Difference between revisions of "Volasertib (BI-6727)"
Jump to navigation
Jump to search
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Intravenous chemotherapy" to "Category:Intravenous medications") |
||
Line 11: | Line 11: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
− | [[Category:Intravenous | + | [[Category:Intravenous medications]] |
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] |
Revision as of 16:48, 25 July 2017
Mechanism of action
Polo-like kinase 1 (PLK1) inhibitor
Preliminary data
Acute myeloid leukemia
- Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlure P, Ottmann OG, Müller-Tidow C, Krämer A, Raffoux E, Döhner K, Schlenk RF, Voss F, Taube T, Fritsch H, Maertens J. Randomized, phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy. Blood. 2014 Aug 28;124(9):1426-33. Epub 2014 Jul 8. link to original article PubMed
History of changes in FDA indication
- 4/14/2014: Granted FDA orphan drug status for treatment of acute myeloid leukemia.